Although plasma GFAP displays a strong correlation with cerebral amyloidosis [16], it is not a specific marker of Alzheimer’s disease pathology and shows diagnostic accuracy in differentiating between healthy controls and individuals with frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, Lewy bodies dementia, and cognitively impaired individuals with suspected non-AD pathophysiology [52]. Here, GFAP is linked to Classical progressive supranuclear palsy.